Lineage Cell Therapeutics
LCTX
LCTX
107 hedge funds and large institutions have $107M invested in Lineage Cell Therapeutics in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 25 increasing their positions, 17 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
2% more capital invested
Capital invested by funds: $105M → $107M (+$2.03M)
7% less funds holding
Funds holding: 115 → 107 (-8)
18% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 33
Holders
107
Holding in Top 10
4
Calls
$52K
Puts
$4K
Top Buyers
| 1 | +$7.48M | |
| 2 | +$2.12M | |
| 3 | +$1.61M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.22M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$926K |
Top Sellers
| 1 | -$2.1M | |
| 2 | -$1.93M | |
| 3 | -$1.09M | |
| 4 |
Jane Street
New York
|
-$808K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$580K |